Want to see HK:0928 full AI Analyst Report?
Top Page
Life Healthcare Group
(0928)
Select Model
Select Model
Rating:52Neutral
Price Target:
HK$1.50
▲(1263.64% Upside)
Action:Reiterated
Date:10/03/26
The score is held back primarily by weak and volatile cash generation despite improving reported profitability, alongside an expensive valuation (P/E 130). Technicals are supportive due to a strong uptrend versus moving averages, but overbought momentum (RSI ~78.7) adds near-term risk.
Positive Factors
Revenue Growth and Profitability
The sharp 2026 revenue increase and return to positive profitability indicate improving operating performance and stronger hospital-service activity. If this recovery persists, greater scale could support reinvestment, improve operating leverage, and strengthen the company’s ability to build sustainable earnings over the next several quarters.
Negative Factors
Weak Cash Conversion
Persistently weak operating and free cash flow means reported earnings are not consistently converting into cash. Continued negative conversion could constrain internally funded investment, increase reliance on external financing, and make the company’s earnings quality and financial flexibility more volatile.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth and Profitability
The sharp 2026 revenue increase and return to positive profitability indicate improving operating performance and stronger hospital-service activity. If this recovery persists, greater scale could support reinvestment, improve operating leverage, and strengthen the company’s ability to build sustainable earnings over the next several quarters.
Read all positive factors
Life Healthcare Group (0928) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$240.56M
Dividend YieldN/A
Average Volume (3M)1.09M
Price to Earnings (P/E)75.9
Beta (1Y)0.72
Revenue Growth251.35%
EPS GrowthN/A
CountryHK
Employees13
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.21
Shares Outstanding555,127,500
10 Day Avg. Volume928,335
30 Day Avg. Volume1,091,731
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)0.59
Price to Sales (P/S)0.98
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Life Healthcare Group Business Overview & Revenue Model
Company Description
King International Investment Limited operates as a holding company, with its core activities focused on the provision of healthcare products and related services. The firm's business interests are diversified, also encompassing money lending and ...
How the Company Makes Money
Life Healthcare Group makes money mainly by providing healthcare services through its hospital operations. Its revenue model is largely service-based: (1) Patient service revenue: The group earns fees from hospital services delivered to patients, ...
Life Healthcare Group Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
78
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 77.50M | 143.23M | 40.77M | 233.68M | 223.85M | 92.87M |
| Gross Profit | 19.52M | 25.37M | 12.73M | 37.79M | 12.05M | 13.75M |
| EBITDA | -10.31M | 9.63M | -10.01M | 27.69M | -26.72M | -29.18M |
| Net Income | -38.45M | 1.84M | -47.45M | 15.82M | -25.19M | -34.46M |
Balance Sheet | ||||||
| Total Assets | 357.20M | 385.17M | 286.36M | 336.13M | 264.27M | 302.94M |
| Cash, Cash Equivalents and Short-Term Investments | 591.00K | 531.00K | 309.00K | 473.00K | 17.79M | 37.40M |
| Total Debt | 2.11M | 7.86M | 2.37M | 5.71M | 6.73M | 422.00K |
| Total Liabilities | 122.40M | 146.96M | 63.72M | 70.08M | 31.27M | 39.56M |
| Stockholders Equity | 234.80M | 238.21M | 222.64M | 269.85M | 237.50M | 262.28M |
Cash Flow | ||||||
| Free Cash Flow | -59.15M | -13.36M | -322.00K | -32.32M | -134.69M | 96.85M |
| Operating Cash Flow | -59.15M | -13.36M | -322.00K | -32.32M | -134.48M | 96.86M |
| Investing Cash Flow | -51.00K | 0.00 | -51.00K | 1.00K | 94.86M | -67.83M |
| Financing Cash Flow | 53.61M | -614.00K | -1.18M | 17.39M | 27.40M | -830.00K |
Life Healthcare Group Technical Analysis
Neutral
0.11
Price Trends
0.68
Positive
0.55
Positive
0.55
Positive
Market Momentum
0.02
Positive
51.14
Neutral
61.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0928, the sentiment is Neutral. The current price of 0.11 is below the 20-day moving average (MA) of 0.80, below the 50-day MA of 0.68, and below the 200-day MA of 0.55, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 51.14 is Neutral, neither overbought nor oversold. The STOCH value of 61.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0928.
Life Healthcare Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$1.53B | 8.54 | 43.78% | 11.97% | -14.68% | -13.60% | |
56 Neutral | HK$1.10B | 78.10 | 0.48% | 1.10% | -3.26% | ― | |
55 Neutral | HK$167.73M | -1.71 | -22.16% | 2.02% | -28.07% | 47.54% | |
52 Neutral | HK$240.56M | 75.92 | 0.78% | ― | 251.35% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$467.79M | -144.52 | -0.41% | ― | 3.16% | -101.02% | |
49 Neutral | HK$681.50M | -1.70 | -25.36% | 1.47% | -8.94% | -140.82% |
* Healthcare Sector Average
HK:0928
Life Healthcare Group
0.76
0.01
1.61%
HK:1830
Perfect Medical Health Management Limited
1.22
-0.05
-4.18%
HK:2138
EC Healthcare
0.58
-0.17
-22.30%
HK:2393
Yestar Healthcare Holdings Co Ltd
0.07
-0.07
-48.57%
HK:3869
Hospital Corporation of China Ltd
3.39
-3.37
-49.85%
HK:3886
Town Health International Medical Group Ltd.
0.16
-0.14
-45.70%
Life Healthcare Group Corporate Events
King International Wins Shareholder Backing for Share Consolidation and Major Rights Issue
Sep 28, 2026
King International Investment Limited has secured shareholder approval for a share consolidation and a rights issue at an extraordinary general meeting held on 28 September 2026, with both resolutions passed by poll with 100% of the votes cast in ...
King International Plans Share Consolidation and Major Rights Issue
Sep 10, 2026
King International Investment Limited has called an extraordinary general meeting for 28 September 2026 in Hong Kong, where shareholders will vote on consolidating every 10 existing shares into one new share with a higher par value. The move will ...
King International Investment Wins Unanimous Shareholder Backing at AGM
Sep 4, 2026
Shareholders of King International Investment Limited have unanimously approved all resolutions at the annual general meeting held on 4 September 2026 in Hong Kong. The meeting covered routine governance matters, including adoption of audited fina...
King International Investment Revises Timetable for Share Consolidation and Rights Issue
Aug 20, 2026
King International Investment Limited has postponed the despatch of its circular on a proposed share consolidation, change of board lot size and rights issue, moving the expected mailing date from 20 August 2026 to on or before 11 September 2026. ...
King International Investment Sets AGM to Approve Accounts, Board Mandates and Share Issue Authority
Jul 31, 2026
King International Investment Limited has called its annual general meeting for 4 September 2026 in Hong Kong, where shareholders will consider routine matters including adoption of the audited financial statements for the year ended 31 March 2026...
King International Plans Share Consolidation and Rights Issue to Raise Capital
Jul 23, 2026
King International Investment Limited plans to consolidate every ten existing shares of HK$0.05 into one consolidated share of HK$0.50, leaving authorised share capital unchanged at HK$500 million but cutting issued shares to about 185 million. Th...
King International Investment Details Director Dispute and Loss of Control Over Healthcare Subsidiaries
Jul 6, 2026
King International Investment Limited has clarified the identities and roles of former executive director Liu Mingqing and former executive director turned non-executive director Yan Ming in relation to control issues at several key healthcare sub...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.